XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.23.1

CIRM Grants | 3 Months Ended
--- | ---
Mar. 31, 2023
CIRM Grants [Abstract] |
CIRM Grants |
15. | CIRM Grants
LAD-1 CIRM Grant On April 30, 2019, the California Institute for Regenerative Medicine (“CIRM”) awarded the Company up to $7.5 million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy for RP-L201. Proceeds from the grant will help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles (“UCLA”) Mattel Children’s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Through March 31, 2023, the Company has received $5.9 million in total RP-L201 grants from CIRM. No additional milestones were achieved as of March 31, 2023.

X
- References No definition available. + Details
Name: | rckt_CIRMGrantsAbstract
Namespace Prefix: | rckt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for California institute for regenerative medicine grants. + References No definition available. + Details
Name: | rckt_CaliforniaInstituteForRegenerativeMedicineGrantsTextBlock
Namespace Prefix: | rckt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration